Document is current
Any future updates will be listed below
-
Authors
Kearney, Matthew
Franks, Lauren
Lee, Shing
Tiersten, Amy
Makower, Della F.
Cigler, Tessa
Mundi, Prabhjot
Chi, Dow-Chung
Goel, Anupama
Klein, Pam
Andreopoulou, Eleni
Sparano, Joseph
Trivedi, Meghna
Accordino, Melissa
Califano, Andrea
Hershman, Dawn L.
Silva, Jose
Kalinsky, Kevin https://orcid.org/0000-0002-1583-3553
-
Funding
Funding for this research was provided by:
Incyte
- License Information
-
More Information
Article History
Received: 28 April 2021
Accepted: 18 June 2021
First Online: 24 June 2021
Declarations
:
: Kevin Kalinsky: Advisory/Consulting: Eli-Lilly, Pfizer, Novartis, Eisai, AstraZeneca, Immunomedics, Merck, Seattle Genetics, OncoSec, 4D Pharma, Daicchi Sankyo, and Cyclocel. Spouse, Stock: Grail, Array BioPharma and Pfizer (prior employee). Amy Tiersten: Consultant/advisory board for Immunomedics, Astrazeneca, Novartis, Eisai, Cyclacel and research funding Pfizer. The other authors declare that they have no conflict of interest.
: This study was conducted with approval from the Institutional Review Board at each enrolling center and is registered under NCT02066532 at ClinicalTrials.gov. All procedures in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
